These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 2432087)

  • 1. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo.
    Devine DV; Siegel RS; Rosse WF
    J Clin Invest; 1987 Jan; 79(1):131-7. PubMed ID: 2432087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.
    Pangburn MK; Schreiber RD; Trombold JS; Müller-Eberhard HJ
    J Exp Med; 1983 Jun; 157(6):1971-80. PubMed ID: 6222136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
    Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
    Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
    Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.
    Devine DV; Rosse WF
    Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5873-7. PubMed ID: 2956607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ; Baker PJ; Rosse WF
    J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
    J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
    Seya T; Inoue H; Okada M; Matsumoto M; Kitamura H; Kinoshita T; Akedo H
    Mol Immunol; 1990 Jan; 27(1):69-78. PubMed ID: 1690349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
    Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
    Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
    Davitz MA; Low MG; Nussenzweig V
    J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Medof ME; Kinoshita T; Silber R; Nussenzweig V
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA).
    Ninomiya H; Abe T; Shichishima T; Terasawa T; Fujita T
    Br J Haematol; 1988 May; 69(1):81-7. PubMed ID: 2454648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunocytochemical staining of decay-accelerating factor (DAF) on erythrocytes: paroxysmal nocturnal hemoglobinuria (PNH)].
    Kobayashi T; Nakazawa M; Sato Y; Tomiyama J; Ninomiya H; Abe T; Terasawa T; Shichishima T; Fujita T
    Rinsho Ketsueki; 1992 Feb; 33(2):162-6. PubMed ID: 1378912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets.
    Dixon RH; Rosse WF
    J Clin Invest; 1977 Feb; 59(2):360-8. PubMed ID: 833281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes.
    Parker CJ; Soldato CM; Rosse WF
    J Clin Invest; 1984 Apr; 73(4):1130-43. PubMed ID: 6231312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-lymphocytes escape membrane defect in paroxysmal nocturnal haemoglobinuria.
    Cooper MR; Currie MS; Rustagi PK; Logue GL
    Br J Haematol; 1983 Oct; 55(2):263-71. PubMed ID: 6604541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional differences between decay-accelerating factor and red cell acetylcholinesterase.
    Sugarman J; Devine DV; Rosse WF
    Blood; 1986 Sep; 68(3):680-4. PubMed ID: 2427138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.